All issues
Volume 60 (2014)
- Issue 6 Pages 213-
- Issue 5 Pages 163-
- Issue 4 Pages 123-
- Issue 3 Pages 85-
- Issue 2 Pages 47-
- Issue 1 Pages 1-
- Issue Suppl.1 Pages S･･･
Volume 60, Issue Suppl.1
Displaying 1-15 of 15 articles from this issue
- |<
- <
- 1
- >
- >|
The 19th Japan Head and Neck Cancer Chemotherapy Conference Group (JHNCCCG)
-
[in Japanese]2014 Volume 60 Issue Suppl.1 Pages S1-S2
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSDownload PDF (549K) -
Shoji NATSUGOE, Yasuto UCHIKADO, Hiroshi OKUMURA2014 Volume 60 Issue Suppl.1 Pages S3-S8
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSThe incidence of multiple carcinomas in the hypopharynx and esophagus has increased recently. Esophageal cancer surgery has safely performed owing to development of surgical instrument and progress of perioperative management. However, it is essential to make a treatment plan under the detailed examination for multiple carcinomas in the hypopharynx and esophagus. There are several surgical methods such as endoscopic submucosal dissection, thoracoscopic surgery, blunt dissection and open surgery. Furthermore, preoperative chemo and/or radiation therapy is applicable for some cases. It is important to determine the treatment strategy for multiple carcinomas in the hypopharynx and esophagus after otolaryngologist and esophageal surgeon discuss in details the tumor stage and patient situation.View full abstractDownload PDF (1164K) -
Kiyoto SHIGA2014 Volume 60 Issue Suppl.1 Pages S9-S12
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSSecond primary malignancy can always be a critical problem to treat head and neck cancer patients. In this study, we analyzed 120 patients with hypopharyngeal cancer to elucidate the coincidence of esophageal cancer as a second primary malignancy and the strategy to treat these patients. There were 21 out of 120 (17.5%) patients with synchronous second primary malignancies who had 24 tumors. There were 13 esophageal cancers in these 21 patients (61.9%). The strategies to treat these patients with hypopharyngeal cancer were not changed by whether or not they had esophageal cancers. As for the timing of the treatment of these esophageal cancers i.e. before or after the radical therapy for hypopharyngeal cancer, or at the same time, strict evaluations were needed for each case to settle it.View full abstractDownload PDF (984K) -
Mitsuhiko NAKAHIRA, Masashi SUGASAWA2014 Volume 60 Issue Suppl.1 Pages S13-S20
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSWe reported a clinical experience of 19 synchronous esophageal cancers in 127 patients with hypopharyngeal cancer initially treated at Saitama Medical University International Medical Center between April 2007 and February 2013. The esophageal cancer was the most popular cancer among cancers synchronously combined with a hypopharyngeal cancer and its incidence was 15 %. The overall 4-year survival rate was 30.9 %, although 42 % patients of esophageal cancers were classified as stage 0 and potentially treatable endoscopically. The present study revealed that main cause of treatment failure was due to fairly advanced diseases of hypopharyngeal cancers accounting for more than 60 % of all cases and an occult lymph node metastasis of early esophageal cancers. In addition, we reported an interesting and successfully-treated case of a synchronous p16 positive oropharyngeal cancer in a patient with multiple synchronous cancers of larynx, hypopharynx and esophagus, although p16 immunohistological study was negative in the esophageal cancer.View full abstractDownload PDF (4696K) -
[in Japanese], [in Japanese], [in Japanese], [in Japanese]2014 Volume 60 Issue Suppl.1 Pages S21-S30
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSDownload PDF (586K)
-
[in Japanese]2014 Volume 60 Issue Suppl.1 Pages S31-S32
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSDownload PDF (552K) -
[in Japanese]2014 Volume 60 Issue Suppl.1 Pages S33-S37
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESS -
Yusuke DEMIZU2014 Volume 60 Issue Suppl.1 Pages S38-S43
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSParticle therapy, such as proton therapy and carbon ion therapy, is capable of delivering high-dose radiation to tumors while minimizing the dose delivered to organs at risk because it emits maximum energy just before stopping in the deep portion of the body. In the head and neck region, particle therapy has been mainly used for photon-resistant tumors, such as malignant melanomas and adenoid cystic carcinomas, and favorable results have been achieved. At the Hyogo Ion Beam Medical Center, where both proton therapy and carbon ion therapy are available, retrospective analyses of clinical outcomes have shown that there are no significant differences between two therapies in either efficacy or toxicity. Owing to its sharper penumbra, carbon ion therapy often demonstrates better dose distribution compared with proton therapy especially in the head and neck region, where is densely-packed with organs at risk. Prospective randomized controlled trials are warranted to elucidate whether there is truly no difference in clinical outcomes between proton therapy and carbon ion therapy; however,performing a prospective study is practically difficult because the main targets of particle therapy are rare tumors.View full abstractDownload PDF (2462K) -
Ichiro OTA2014 Volume 60 Issue Suppl.1 Pages S44-S51
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSBoron Neutron Capture Therapy (BNCT) is the next generation radiotherapy to selectively destroy only cancer cells by using a reaction of boron-neutron. It is possible to kill the cancer cells only, as a minimally invasive therapy, without giving much damage to the surrounding normal cells, by selectively incorporated boron compound into cancer cells and irradiated them with thermal neutrons. BNCT is suitable for malignant brain tumors or recurrent head and neck cancers with radiation resistance. The cyclotron-based epithermal-neutron source is a promising alternative to reactor-based neutron sources for treatments by BNCT.View full abstractDownload PDF (2416K) -
[in Japanese], [in Japanese], [in Japanese], [in Japanese]2014 Volume 60 Issue Suppl.1 Pages S52-S60
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSDownload PDF (580K)
-
[in Japanese]2014 Volume 60 Issue Suppl.1 Pages S61-S62
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSDownload PDF (550K) -
Kazuaki CHIKAMATSU2014 Volume 60 Issue Suppl.1 Pages S63-S69
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSIn addition to identifying tumor-associated antigens, elucidation of the dynamic interactions between the immune system and tumor cells has contributed to the development of cancer immunotherapy. Based on novel findings from basic immunology, numerous immunotherapeutic approaches are currently being tested as cancer treatments, and the number of cancer immunotherapies in clinical trials has risen sharply in the last two decades. Several cancer immunotherapies in phase III clinical trials have shown objective tumor regression as well as enhanced anti-tumor immune responses. Through these clinical trials, the first patient-specific cellular immunotherapy, Sipuleucel-T (Provenge) was approved by the US Food and Drug Administration (FDA) for the treatment of prostate cancer in 2010. Moreover, anti-cytotoxic T-lymphocyte antigen 4(CTLA-4) antibody (Ipilimumab), which works by activating the immune system by blocking immune checkpoints, was also approved by the FDA for the treatment of melanoma in 2011. In the near future, immunotherapeutic modalities to overcome tumor-induced immune resistance and immune suppression will be developed and applied as novel approaches in the treatment of head and neck cancer. Herein, four topics in tumor immunology, namely, cancer immunoediting,cancer vaccines, chimeric antigen receptor (CAR) T cell therapy, and immune checkpoint inhibitors are discussed.View full abstractDownload PDF (1321K) -
Nobuhiko ORIDATE, Hideaki TAKAHASHI, Hiroshi HYAKUSOKU, Daisuke SANO2014 Volume 60 Issue Suppl.1 Pages S70-S74
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSRadioresistance remains a critical issue in the use of radiotherapy for the treatment of head and neck squamous cell carcinoma (HNSCC). This study evaluated the efficacy of combination treatment with OBP-301, a telomerase-specific replication-selective adenovirus, and radiotherapy in overcoming radioresistance by examining its effect on radiation-resistant HNSCC cells. Radiation-resistant HNSCC cells were treated with OBP-301 and radiation in vitro and in an orthotopic nude mouse model in vivo and synergism was assessed. Apoptosis and expression of MRN complex, which plays a key role in DNA repair machinery, were also analyzed. Infection with OBP-301 was found to enhance the antitumor efficacy of radiation both in vitro and in vivo by inhibiting MRN complex expression and increasing apoptosis induction. Combined OBP-301 and radiation therapy seems to overcome radioresistance in HNSCC cells by inhibiting DNA repair machinery, and may thus be a novel therapeutic strategy for treating HNSCC.View full abstractDownload PDF (3711K) -
Susumu OKANO2014 Volume 60 Issue Suppl.1 Pages S75-S79
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSAlong with the evolution of chemotherapy in carcinoma of head and neck region, approvals on drugs newly used in the relative treatments have been extended. Accordingly, various issues including improvement in treatment results, decrease of adverse events, simple methods, cost cut, etc. are required to be solved under the proper way of using the drugs. Paclitaxel was approved in March 2012, and Cetuximab, a molecular target drug, was approved in December in the same year in succession. Paclitaxel has been used for more than 10 years, and cetuximab has been used for several years in the treatments for other regions. However, they are new to us,otorhinolaryngologists/head and neck surgeons, who have no experience using them. We can introduce them to general medical practice smoothly by well comprehending the clinical trial results already reported and the trend of the treatment development, as well as understanding the development chronology and basic knowledge of the drugs.View full abstractDownload PDF (695K) -
[in Japanese], [in Japanese], [in Japanese], [in Japanese]2014 Volume 60 Issue Suppl.1 Pages S80-S87
Published: November 20, 2014
Released on J-STAGE: January 08, 2016
JOURNAL FREE ACCESSDownload PDF (578K)
- |<
- <
- 1
- >
- >|